full-year result unit state go sg websit
slightli better tax reform help stronger guidanc
sale benefit cancer inflamm cardio product
off-set still-declin remicad soft consum
except charg reflect tax reform better adjust ep
strong guidanc rais estim reflect stronger
lower tax rate lift tp howev
reiter hold rate growth slower sector although
visibl good due compani size diversif
revenu publish januari grew constant currenc exclud
acquisit mainli actelion medic optic came
consensu mainli explain better med-tech despit softer consum see next
page robust growth pharma despit declin remicad sale pharma perform
line consensu due actelion acquisit mainli result
robust perform oncolog divis darzalex blood cancer increas
fy sale driven share increas second- third-lin treatment
similarli imbruvica blood cancer increas yoy due strong uptak region
zytiga prostat grew hand remicad anti-inflammatori product
fell mostli due price declin new competit biosimilar ex-u pah
asset acquir actelion increas world-wid us ex-u
mainli due gener competit tracleer adjust ep grew
constant currenc beat consensu howev one-tim provision
charg due recently-enact tax legisl result net loss
ep report basi compani said benefit lower tax rate
lower increas budget
better-than-expect guidanc sale oper growth
adjust ep growth
compani guidanc includ gener competit procrit tracleer remicad
upsid tp
nc chang
rais forecast reflect stronger oncolog growth lower tax
tp gener competit loom zytiga remicad
sale zytiga lost case lower court januari appeal like
day revenu public us appeal court upheld rule invalid
jnj patent remicad howev expect remicad franchis continu
declin biosimilar us zytiga impact us gener
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
simplifi main product
medic devic diagnost
sg cross asset research/equity/ street account consensu organ exclud net impact acquisit divestitur currenc fluctuat
sale breakdown segment
organ sale growth segment
main takeaway confer call januari
darzalex blood cancer reach sale financi year end decemb
continu growth path emea latam region
imbruvica leukaemia revenu increas yoy driven growth market share
us strong uptak outsid us
zytiga prostat cancer growth excess larg driven clinic data
latitud studi zytiga market share castration-resist prostat
cancer market improv compar period januari lower
court invalid us patent describ method administ zytiga
process describ obviou compani appeal decis higher
court final decis expect anoth one two year least factor
us sale declin model
stelara psoriasi mainli grew back expans us immunolog
market strong perform crohn diseas indic howev growth
neg affect due prior quarter rebat cannibalis tremfya next
tremfya psoriasi direct competitor novarti cosentyx lilli talz revenu
came alreadi new-to-brand share leader six month
remicad anti-tnf declin us global
result competit biosimilar howev compani wit lesser impact sale
due biosimilar expect us compani still manag hold
market share volum declin mainli relat price januari us appeal
court invalid crucial patent cover activ ingredi concept
cover prior patent alreadi expir could trigger launch pfizer
alreadi approv biosimilar may follow mani copi forecast doubl
declin core case year anyway
xarelto cardio growth almost result increas total prescript
market share almost versu year ago cours support partner
 compani expect approv apalutamid file approv esketamin
depress addit result lower tax us earn
compani intend increas invest interestingli notic
partner legend biotech compani china develop investig t-cell
anti-cancer therapi multipl myeloma howev far behind leader field
consum compani expect consum busi grow faster rate vs
expect sale shift e-commerc tri cement
leadership posit certain categori geographi
increas estim reflect robust cancer perform lower tax rate
valuat tp price increas vs
averag us pharma pharma premium
consum
new york mellon corp
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet jan cet
new york mellon bk reco
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
deriv target price sotp us larg pharma multipl premium consum med-tech line
pharma dcf lt growth lt ebita margin wacc
stock-specif downsid risk non-pharma activ could becom volatil tougher price environ could weigh margin
flat sale would high single-digit neg impact earn due lower margin lead cardio product xarelto could
face pressur bms/pfe eliqui low single-digit neg impact remicad stronger biosimilar impact low singl digit
neg impact product liabil med-tech orthopaed xarelto start alreadi
upsid risk prolong litig may delay launch gener tail portfolio cancer pharma side take-up biosimilar
compet remlicad could prove slower expect mid-single-digit posit impact earn event softer
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ bond
